Cafelkibart Biosimilar – Anti-CKR-L1 mAb – Research Grade from ProteoGenix; catalogue PX-TA2175; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Cafelkibart Biosimilar – Anti-CKR-L1 mAb – Research Grade
Cafelkibart Biosimilar – Anti-CKR-L1 mAb is a therapeutic antibody that has been developed as a biosimilar to the original anti-CKR-L1 monoclonal antibody (mAb). This biosimilar has been designed to target the same therapeutic target as the original antibody, but with improved structure and activity. In this article, we will discuss the structure, activity, and potential applications of this biosimilar in the field of therapeutic antibody research.
The Cafelkibart Biosimilar – Anti-CKR-L1 mAb is a monoclonal antibody that is produced in a similar way to the original anti-CKR-L1 mAb. It is a protein molecule with a specific structure that allows it to bind to its therapeutic target, the CKR-L1 protein. The biosimilar has been engineered to have a similar structure to the original antibody, but with some modifications to improve its activity and stability.
The biosimilar consists of two heavy chains and two light chains that are connected by disulfide bonds. These chains are made up of amino acids, which are the building blocks of proteins. The amino acid sequence of the biosimilar has been carefully designed to ensure that it can bind specifically to the CKR-L1 protein and exert its therapeutic effects.
The main activity of Cafelkibart Biosimilar – Anti-CKR-L1 mAb is to bind to the CKR-L1 protein and block its function. The CKR-L1 protein is a cell surface receptor that plays a role in inflammatory processes and has been implicated in various diseases such as rheumatoid arthritis and multiple sclerosis. By binding to the CKR-L1 protein, the biosimilar prevents it from interacting with its natural ligands and thus inhibits its signaling pathways.
The improved structure of the biosimilar allows it to have a higher binding affinity for the CKR-L1 protein compared to the original antibody. This means that lower doses of the biosimilar can be used to achieve the same therapeutic effect, reducing the risk of side effects and making it more cost-effective.
The potential applications of Cafelkibart Biosimilar – Anti-CKR-L1 mAb are vast, as the CKR-L1 protein has been implicated in various diseases. The biosimilar can be used in the treatment of inflammatory conditions such as rheumatoid arthritis, multiple sclerosis, and psoriasis. It can also be used in the treatment of certain types of cancer, as the CKR-L1 protein has been found to play a role in tumor growth and metastasis.
Furthermore, the biosimilar can also be used in research studies to better understand the role of the CKR-L1 protein in different diseases and to develop new therapeutic approaches targeting this protein.
In conclusion, Cafelkibart Biosimilar – Anti-CKR-L1 mAb is a promising therapeutic antibody that has been developed as a biosimilar to the original anti-CKR-L1 mAb. Its improved structure and activity make it a powerful tool for targeting the CKR-L1 protein and potentially treating various diseases. With further research and clinical trials, this biosimilar has the potential to become a valuable addition to the field of therapeutic antibody research.
ProteoGenix catalogue number PX-TA2175. For research use only.
Target: Cafelkibart Biosimilar – Anti-CKR-L1 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >95% by SDS-PAGE; Buffer: 0.01M PBS, pH 7.4.
Available configurations: 50ug, 100ug, 1mg.
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
